Literature DB >> 24794262

Epidemiologic trends in head and neck cancer and aids in diagnosis.

Nadarajah Vigneswaran1, Michelle D Williams2.   

Abstract

Head and neck squamous cell carcinoma is the sixth most common cancer worldwide predominately associated with tobacco use. Changing cause and increased incidence in oropharyngeal carcinomas is associated with high-risk types of human papilloma virus and has an improved survival. Optical devices may augment visual oral examination; however, their lack of specificity still warrants tissue evaluation/biopsy. Histologic factors of oral carcinomas are critical for patient management and prognostic determination. Clinical biomarkers are still needed to improve early detection, predict malignant transformation, and optimize therapies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Epidemiologic trends; Head and neck cancer; Squamous cell carcinomas

Mesh:

Substances:

Year:  2014        PMID: 24794262      PMCID: PMC4040236          DOI: 10.1016/j.coms.2014.01.001

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  67 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

Review 3.  Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics.

Authors:  Ann M Gillenwater; Nadarajah Vigneswaran; Hanadi Fatani; Pierre Saintigny; Adel K El-Naggar
Journal:  Head Neck       Date:  2014-08-28       Impact factor: 3.147

4.  Treatment of cT1N0M0 tongue cancer: outcome and prognostic parameters.

Authors:  Tao Zhang; Joshua E Lubek; Andrew Salama; Donita Dyalram; Xinggang Liu; Robert A Ord
Journal:  J Oral Maxillofac Surg       Date:  2013-09-14       Impact factor: 1.895

Review 5.  Natural history of potentially malignant oral lesions and conditions: an overview of the literature.

Authors:  Séamus S Napier; Paul M Speight
Journal:  J Oral Pathol Med       Date:  2008-01       Impact factor: 4.253

6.  Never-smokers, never-drinkers: unique clinical subgroup of young patients with head and neck squamous cell cancers.

Authors:  Stephen L Harris; Randall J Kimple; D Neil Hayes; Marion E Couch; Julian G Rosenman
Journal:  Head Neck       Date:  2010-04       Impact factor: 3.147

7.  Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma.

Authors:  Anthony Po-Wing Yuen; Chiu Ming Ho; Tam Lin Chow; Lap Chiu Tang; Wing Yung Cheung; Raymond Wai-Man Ng; William Ignace Wei; Chi Kwan Kong; Kwok Shing Book; Wai Cheung Yuen; Alfred King-Yin Lam; Nancy Wah-Fun Yuen; Nigel Jeremy Trendell-Smith; Yue Wai Chan; Birgitta Yee-Hang Wong; George Kam-Hop Li; Ambrose Chung-Wai Ho; Wai Kuen Ho; Sau Yan Wong; Tzy-Jyun Yao
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

Review 8.  Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis.

Authors:  Hisham M Mehanna; Tim Rattay; Joel Smith; Christopher C McConkey
Journal:  Head Neck       Date:  2009-12       Impact factor: 3.147

9.  Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation.

Authors:  Caroline Masserot; Régis Peffault de Latour; Vanderson Rocha; Thierry Leblanc; Arnaud Rigolet; Francis Pascal; Anne Janin; Jean Soulier; Eliane Gluckman; Gérard Socié
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

10.  Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.

Authors:  Nabil F Saba; Selwyn J Hurwitz; Scott A Kono; Chung S Yang; Yang Zhao; Zhengjia Chen; Gabe Sica; Susan Müller; Rachel Moreno-Williams; Melinda Lewis; William Grist; Amy Y Chen; Charles E Moore; Taofeek K Owonikoko; Suresh Ramalingam; Jonathan J Beitler; Sreenivas Nannapaneni; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-03
View more
  207 in total

1.  Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia.

Authors:  P N Floriano; T Abram; L Taylor; C Le; H Talavera; M Nguyen; R Raja; A Gillenwater; J McDevitt; N Vigneswaran
Journal:  Oral Dis       Date:  2015-04-06       Impact factor: 3.511

2.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin J Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Mark Lynch; Vijayvel Jayaprakash; Li Li; Maura L Gillison
Journal:  Oral Oncol       Date:  2018-04-17       Impact factor: 5.337

3.  Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.

Authors:  Ariel L Hernandez; Ying Wang; Hilary L Somerset; Stephen B Keysar; Dara L Aisner; Carrie Marshall; Daniel W Bowles; Sana D Karam; David Raben; Antonio Jimeno; Marileila Varella-Garcia; Xiao-Jing Wang
Journal:  Mol Carcinog       Date:  2019-01-16       Impact factor: 4.784

4.  HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Authors:  Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

5.  The two-week wait - a qualitative analysis of suspected head and neck cancer referrals.

Authors:  S Roy; K Anjum
Journal:  Br Dent J       Date:  2018-07-27       Impact factor: 1.626

6.  The frequency of high-risk human papillomavirus types, HPV16 lineages, and their relationship with p16INK4a and NF-κB expression in head and neck squamous cell carcinomas in Southwestern Iran.

Authors:  Fatemeh Pakdel; Ali Farhadi; Tahereh Pakdel; Azadeh Andishe-Tadbir; Parnian Alavi; Abbas Behzad-Behbahani; Mohammad J Ashraf
Journal:  Braz J Microbiol       Date:  2020-11-09       Impact factor: 2.476

7.  Impact of Age on Disease Progression and Microenvironment in Oral Cancer.

Authors:  V K Vincent-Chong; H DeJong; L J Rich; A Patti; M Merzianu; P A Hershberger; M Seshadri
Journal:  J Dent Res       Date:  2018-05-11       Impact factor: 6.116

Review 8.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

9.  Impact of Smoking on the Survival of Patients With High-risk HPV-positive HNSCC: A Meta-analysis.

Authors:  Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Synthesis and antitumor activity of bis(hydroxymethyl)propionate analogs of pterostilbene in cisplatin-resistant human oral cancer cells.

Authors:  Min-Tsang Hsieh; Li-Jiau Huang; Tian-Shung Wu; Hui-Yi Lin; Susan L Morris-Natschke; Kuo-Hsiung Lee; Sheng-Chu Kuo
Journal:  Bioorg Med Chem       Date:  2018-06-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.